Loading clinical trials...
Loading clinical trials...
A Prospective, Observational Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake /Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant as a Control Arm for the Safety Assessments in the Seltorexant Phase 3 Program
Conditions
Interventions
Standard of Care (SOC)
Locations
4
United States
University of California San Francisco
San Francisco, California, United States
Brigham And Women's Hospital
Boston, Massachusetts, United States
The University of Pittsburgh of the Commonwealth System of Higher Education
Pittsburgh, Pennsylvania, United States
Warneford Hospital
Oxford, United Kingdom
Start Date
October 26, 2021
Primary Completion Date
October 19, 2022
Completion Date
October 19, 2022
Last Updated
April 27, 2025
NCT07227454
NCT05415397
NCT07059234
NCT06396312
NCT06136546
NCT06621394
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions